Malignant solid tumor with BRAF V600E mutation

A malignant solid tumor with a *BRAF* V600E mutation represents a tumor-agnostic oncologic condition characterized by solid-organ malignancies harboring an activating missense mutation in the *BRAF* oncogene, where valine is substituted by glutamic acid at codon 600 This alteration occurs across diverse tissues and organ systems, including the central nervous system, biliary tree, thyroid, skin, gastrointestinal tract, and lungs, occurring in both adult and pediatric populations Pathophysiologic...

A malignant solid tumor with a *BRAF* V600E mutation represents a tumor-agnostic oncologic condition characterized by solid-organ malignancies harboring an activating missense mutation in the *BRAF* oncogene, where valine is substituted by glutamic acid at codon 600 Pathophysiologically, the V600E substitution constitutively activates the downstream MAPK/ERK signaling pathway independently of upstream RAS signaling, driving unregulated cellular proliferation, evasion of apoptosis, and invasive m...

This alteration occurs across diverse tissues and organ systems, including the central nervous system, biliary tree, thyroid, skin, gastrointestinal tract, and lungs, occurring in both adult and pediatric populations

Clinically, tumors exhibiting this genomic signature tend to display heightened biological aggressiveness, poorer conventional prognosis, and specialized therapeutic susceptibility to targeted RAF pathway inhibition

Clinically, tumors exhibiting this genomic signature tend to display heightened biological aggressiveness, poorer conventional prognosis, and specialized therapeutic susceptibility to targeted RAF pathway inhibition